Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer
- Evaluate the validity of determining CA 15-3 levels in the cerebrospinal fluid (CSF)
using automated immuno-enzymatic methods.
- Determine the sensitivity and specificity of these assays in assessing CA 15-3 in CSF.
- Assess favorability of intrathecal production of CA 15-3.
- Determine threshold interpretations of CA 15-3 levels in CSF.
OUTLINE: This is a multicenter study.
Within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are
collected. Samples are examined by immunoenzyme assays. Patients with suspected cases of
carcinomatous meningitis undergo cerebrospinal MRI.
- Meets 1 of the following criteria:
- Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous
meningitis, with or without brain metastasis
- Other type of cancer with evidence suggestive of carcinomatous meningitis
- Meningeal syndrome without context of cancer
- No other prior cancers
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
- No prior intrathecal treatment
- At least 4 weeks since prior interferon
- No concurrent participation in another clinical trial
Type of Study:
Masking: Open Label, Primary Purpose: Diagnostic
CA 15-3 levels in cerebrospinal fluid
Emilie Le Rhun
Centre Oscar Lambret
- Brain and Central Nervous System Tumors
- Breast Cancer
- Metastatic Cancer
- leptomeningeal metastases
- male breast cancer
- stage IV breast cancer
- tumors metastatic to brain
- adult meningioma
- Breast Neoplasms
- Neoplasm Metastasis
- Neoplasms, Second Primary
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Meningeal Carcinomatosis